| Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. | |
| | |
MedLine Citation:
|
PMID: 15025747 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Omeprazole is mainly metabolized by the polymorphic cytochrome P450 (CYP) 2C19. The inhibitory effect of fluvoxamine, an inhibitor of CYP2C19 as well as CYP1A2, on the metabolism of omeprazole was compared between different genotypes for CYP2C19. METHODS: Eighteen volunteers, of whom six were homozygous extensive metabolizers (EMs), six were heterozygous EMs and six were poor metabolizers (PMs) for CYP2C19, participated in the study. A randomized double-blind, placebo-controlled crossover study was performed. All subjects received two six-day courses of either daily 50 mg fluvoxamine or placebo in a randomized fashion with a single oral 40 mg dose of omeprazole on day six in both cases. Plasma concentrations of omeprazole and its metabolites, 5-hydroxyomeprazole, omeprazole sulphone, and fluvoxamine were monitored up to 8 h after the dosing. RESULTS: During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively. Fluvoxamine treatment increased C(max) of omeprazole by 3.7-fold (95%CI, 2.4, 5.0-fold, P < 0.01) and 2.0-fold (1.4, 2.6-fold, P < 0.01), AUC(0,8 h) by 6.0-fold (3.3, 8.7-fold, P < 0.001) and 2.4-fold (1.7, 3.2-fold, P < 0.01), AUC(0, infinity ) by 6.2-fold (3.0, 9.3-fold, P < 0.01) and 2.5-fold (1.6, 3.4-fold, P < 0.001) and prolonged t((1/2)) by 2.6-fold (1.9, 3.4-fold, P < 0.001) and 1.4-fold (1.02, 1.7-fold, P < 0.05), respectively. However, no pharmacokinetic parameters were changed in PMs. The AUC(0,8 h) ratios of 5-hydroxyomeprazole to omeprazole were decreased with fluvoxamine in homozygous EMs (P < 0.05) and heterozygous EMs (P < 0.01). CONCLUSIONS: Even a low dose of fluvoxamine increased omeprazole exposure in EMs, but did not increase omeprazole exposure in PMs after a single oral dose of omeprazole. These findings confirm a potent inhibitory effect of fluvoxamine on CYP2C19 activity. The bioavailability of omeprazole might, to some extent, be increased through inhibition of P-glycoprotein during fluvoxamine treatment. |
| | |
Authors:
|
Norio Yasui-Furukori; Takenori Takahata; Taku Nakagami; Gen Yoshiya; Yoshimasa Inoue; Sunao Kaneko; Tomonori Tateishi |
Related Documents
:
|
15674097 - Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effective... 15687727 - Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles ... 22691467 - Decontamination of green onions and baby spinach by vaporized ethyl pyruvate. 10593167 - Monitoring of the thromboxane a2/prostacyclin ratio in the urine of patients with retin... 20517847 - Ciclosporin for severe refractory colitis. 16061627 - Radiation damage to the heart enhances early radiation-induced lung function loss. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: 57 ISSN: 0306-5251 ISO Abbreviation: Br J Clin Pharmacol Publication Date: 2004 Apr |
Date Detail:
|
Created Date: 2004-03-17 Completed Date: 2004-07-12 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 487-94 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacology, Hirosaki University, School of Medicine, Hirosaki, Japan. yasufuru@cc.hirosaki-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anti-Ulcer Agents / antagonists & inhibitors* Aryl Hydrocarbon Hydroxylases / genetics* Cross-Over Studies Double-Blind Method Drug Interactions Female Fluvoxamine / pharmacology* Heterozygote Homozygote Humans Male Mixed Function Oxygenases / genetics* Omeprazole / antagonists & inhibitors* Serotonin Uptake Inhibitors / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Ulcer Agents; 0/Serotonin Uptake Inhibitors; 54739-18-3/Fluvoxamine; 73590-58-6/Omeprazole; EC 1.-/Mixed Function Oxygenases; EC 1.14.14.1/Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1/CYP2C19 protein, human |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.
Next Document: Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xan...